Variants in mannose-binding lectin and tumour necrosis factor α affect survival in cystic fibrosis

Journal of Medical Genetics

Volumn 44, Issue 3, 2007, Pages 209-214

  Buranawuti, Kitti ^b   Boyle, Michael P ^b   Cheng, Suzanne ^c   Steiner, Lori L ^c   McDougal, Kathryn ^b   Fallin, M Daniele ^d   Merlo, Christian ^b   Zeitlin, Pamela L ^b   Rosenstein, Beryl J ^b   Mogayzel Jr , Peter J ^b   Wang, Xinjing ^b   Cutting, Garry R ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ROCHE MOLECULAR SYSTEMS   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LYMPHOTOXIN; MANNOSE BINDING LECTIN; TRANSFORMING GROWTH FACTOR BETA1; TRANSMEMBRANE CONDUCTANCE REGULATOR; TUMOR NECROSIS FACTOR ALPHA; MBL2 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CAUCASIAN; CHILD; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE FREE SURVIVAL; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; GEOGRAPHIC ORIGIN; HAZARD RATIO; HUMAN; INFANT; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEWBORN; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; GENETICS; PHENOTYPE; SURVIVAL; SURVIVOR;

ADOLESCENT; ADULT; CHILD; CYSTIC FIBROSIS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MANNOSE-BINDING LECTIN; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; SURVIVORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34147103990     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.2006.046318     Document Type: Article

References (30)

1. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry Annual Data Report 2001. 9-1, 2002.
2. Kerem E, Corey M, Gold R, Levison H. Pulmonary function and clinical course in patients with CF after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr 1990;116:714-19.
3. Corey M, Edwards L, Levison H, Knowles M. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr 1997;131:809-14.
4. Lai HJ, Cheng Y, Cho H, Kosorok MR, Farrell PM. Association between initial disease presentation, lung disease outcomes, and survival in patients with cystic fibrosis. Am J Epidemiol 2004;159:537-46.
5. Sharma R, Florea VG, Bolger AP, Doehner W, Florea ND, Coats AJ, Hodson ME, Anker SD, Henein MY. Wasting as an independent predictor of mortality in patients with cystic fibrosis. Thorax 2001;56:746-50.
6. O'Connor GT, Quinton HB, Kneeland T, Kahn R, Lever T, Maddock J, Robichaud P, Detzer M, Swartz DR. Median household income and mortality rate in cystic fibrosis. Pediatrics 2003;111(4 Pt 1):e333-9.
7. McKone EF, Emerson SS, Edwards KL, Aitken ML. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet 2003;361:1671-6.
8. Cutting GR. Modifier genetics: cystic fibrosis. Annu Rev Genomics Hum Genet 2005;6:237-60.
9. Garred P, Pressler T, Madsen HO, Frederiksen B, Svejgaard A, Hoiby N, Schwartz M, Koch C. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest 1999;104:431-7.
10. Garred P, Larsen F, Seyfarth J, Fujita R, Madsen HO. Mannose-binding lectin and its genetic variants. Genes Immun 2006;7:85-94.
11. Gabolde M, Guilloud-Bataille M, Feingold J, Besmond C. Association of variant alleles of mannose binding lectin with severity of pulmonary disease in cystic fibrosis: cohort study. Br Med J 1999;319:1166-7.
12. Yarden J, Radojkovic D, De Boeck K, Macek M Jr, Zemkova D, Vavrova V, Vlietinck R, Cassiman JJ, Cuppens H. Polymorphisms in the mannose binding lectin gene affect the cystic fibrosis pulmonary phenotype. J Med Genet 2004;41:629-33.
13. Trevisiol C, Boniotto M, Giglio L, Poli F, Morgutti M, Crovella S. MBL2 polymorphisms screening in a regional Italian CF Center. J Cyst Fibros 2005;4:189-91.
14. Muhlebach MS, MacDonald SL, Button B, Hubbard JJ, Turner ML, Boucher RC, Kilpatrick DC. Association between mannan-binding lectin and impaired lung function in cystic fibrosis may be age-dependent. Clin Exp Immunol 2006;145:302-7.
15. Hull J, Thomson AH. Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis. Thorax 1998;53:1018- 21.
16. Yarden J, Radojkovic D, De Boeck K, Macek M Jr, Zemkova D, Vavrova V, Vlietinck R, Cassiman JJ, Cuppens H. Association of rumour necrosis factor alpha variants with the CF pulmonary phenotype. Thorax 2005;60:320-5.
17. Arkwright PD, Laurie S, Super M, Pravica V, Schwarz MJ, Webb AK, Hutchinson IV. TGF-beta(1) genotype and accelerated decline in lung function of patients with cystic fibrosis [see comments]. Thorax 2000;55:459- 62.
18. Drumm ML, Konstan MW, Schluchter MD, Handler A, Pace R, Zou F, Zariwala M, Fargo D, Xu A, Dunn JM, Darrah RJ, Dorfman R, Sandford AJ, Corey M, Zielenski J, Durie P, Goddard K, Yankaskas JR, Wright FA, Knowles MR. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 2005;353:1443-53.
19. Cowan MJ, Huang X, Yao XL, Shelhamer JH. Tumor necrosis factor alpha stimulation of human Clara cell secretory protein production by human airway epithelial cells. Ann N Y Acad Sci 2000;923:193-201
20. Lora JM, Zhang DM, Liao SM, Burwell T, King AM, Barker PA, Singh L, Keaveney M, Morgenstern J, Gutierrez-Ramos JC, Coyle AJ, Fraser CC. TNF-alpha triggers mucus production in airway epithelium through an IKKbeta dependent mechanism. J Biol Chem 2005;280(43):36510-17.
21. Chmiel JF, Berger M, Konstan MW. The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol 2002;23:5-27.
22. Baxter N, Sumiya M, Cheng S, Erlich H, Regan L, Simons A, Summerfield JA. Recurrent miscarriage and variant alleles of mannose binding lectin, tumour necrosis factor and lymphotoxin alpha genes. Clin Exp Immunol 2001;126:529-34.
23. Wang X, Myers A, Saiki RK, Cutting GR. Development and evaluation of a PCR-based, line probe assay for the detection of 58 alleles in the cystic fibrosis transmembrane conductance regulator (CFTR) Gene. Clin Chem 2002;48:1121-3.
24. Davies JC, Griesenbach U, Alton E. Modifier genes in cystic fibrosis. Pediatr Pulmonol 2005;39:383-91.
25. Davies JC, Turner MW, Klein N. Impaired pulmonary status in cystic fibrosis adults with two mutated MBL-2 alleles. Eur Respir J 2004;24:798-804.
26. Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss CH, Aitken ML. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med 2002;166(12 Pt 1):1550-5.
27. Kaluza W, Reuss E, Grossmann S, Hug R, Schopf RE, Galle PR, Maerker-Hermann E, Hoehler T. Different transcriptional activity and in vitro TNF-alpha production in psoriasis patients carrying the TNF-alpha 238A promoter polymorphism. J Invest Dermatol 2000;114:1180-3.
28. Fong CL, Siddiqui AH, Mark DF. Identification and characterization of a novel repressor site in the human tumor necrosis factor alpha gene. Nucleic Acids Res 1994;22:1108-14.
29. Knight JC, Udalova I, Hill AV, Greenwood BM, Peshu N, Marsh K, Kwiatkowski D. A polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria. Nat Genet 1999;22:145- 50.
30. Koehler DR, Downey GP, Sweezey NB, Tanswell AK, Hu J. Lung inflammation as a therapeutic target in cystic fibrosis. Am J Respir Cell Mol Biol 2004;31:377-81.